Goldman Sachs
LYEL icon

Goldman Sachs’s Lyell Immunopharma LYEL Stock Holding History

Goldman Sachs’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
114,491
+17,816
+18% +$416K ﹤0.01% 4419
2025
Q4 		$2.98M Buy
+96,675
New +$2.16M ﹤0.01% 4239
2025
Q2 		– Sell
-17,930
Closed -$193K – 6284
2025
Q1 		$193K Sell
17,930
-13,436
-43% -$165K ﹤0.01% 5649
2024
Q4 		$401K Sell
31,366
-10,250
-25% -$203K ﹤0.01% 5359
2024
Q3 		$1.15M Buy
41,616
+24,165
+138% +$710K ﹤0.01% 4543
2024
Q2 		$506K Sell
17,451
-3,833
-18% -$182K ﹤0.01% 4827
2024
Q1 		$949K Sell
21,284
-10,101
-32% -$433K ﹤0.01% 4385
2023
Q4 		$1.22M Buy
31,385
+4,504
+17% +$162K ﹤0.01% 4271
2023
Q3 		$790K Sell
26,881
-5,920
-18% -$281K ﹤0.01% 4407
2023
Q2 		$2.09M Buy
32,801
+5,024
+18% +$278K ﹤0.01% 3852
2023
Q1 		$1.31M Sell
27,777
-32,852
-54% -$1.76M ﹤0.01% 4185
2022
Q4 		$4.21M Buy
60,629
+41,368
+215% +$4.11M ﹤0.01% 3322
2022
Q3 		$2.82M Buy
19,261
+9,191
+91% +$1.24M ﹤0.01% 3660
2022
Q2 		$1.31M Buy
10,070
+752
+8% +$76.8K ﹤0.01% 4403
2022
Q1 		$941K Buy
9,318
+4,112
+79% +$498K ﹤0.01% 4867
2021
Q4 		$806K Buy
+5,206
New +$1.16M ﹤0.01% 5029
2021
Q3 		– Sell
-10,102
Closed -$3.28M – 6393
2021
Q2 		$3.28M Buy
+10,102
New +$3.31M ﹤0.01% 3737

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's LYEL Position: Q1 2026 in Review

Goldman Sachs increased its Lyell Immunopharma (LYEL) stake by 18% in Q1 2026, buying an estimated $416K and bringing the position to 114,491 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4419.

Goldman Sachs first reported a position in LYEL in Q2 2021 and has held it in 17 quarters since. The position peaked at $4.21M in Q4 2022. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Goldman Sachs held 114,491 shares of Lyell Immunopharma worth $2.3M as of Q1 2026.
  • Goldman Sachs bought 17,816 Lyell Immunopharma shares in Q1 2026, an estimated $416K.
  • Lyell Immunopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4419 holding.
  • Goldman Sachs first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 17 quarters since.
  • Goldman Sachs's Lyell Immunopharma position peaked at $4.21M in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.